Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study

Table 2

Anti-TNFi Ab in rheumatoid arthritis patients in remission treated with infliximab or adalimumab.

	Infliximab; = 44	Adalimumab; = 49
Anti-TNFi Ab-pos, % (95% CI)	18 (7–30); ( = 8)	2 (NA); ( = 1)	0.012